The Somewhat Favorable News Coverage Somewhat Unlikely to Impact Oxford Immunotec Global PLC (OXFD) Stock Price

The Somewhat Favorable News Coverage Somewhat Unlikely to Impact Oxford Immunotec Global PLC (OXFD) Stock Price

Here are some of the news stories that may have effected AlphaOne Sentiment Analysis’s rankings:

News articles about Oxford Immunotec Global PLC (NASDAQ:OXFD) have been trending somewhat positive on Monday, according to Alpha One Sentiment Analysis. The research firm, a subsidiary of Accern, ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global PLC earned a news sentiment score of 0.25 on Alpha One’s scale. Alpha One also assigned news stories about the company an impact score of 44 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

A number of analysts have recently weighed in on OXFD shares. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday. BTIG Research reaffirmed a “buy” rating and set a $19.00 price target on shares of Oxford Immunotec Global PLC in a research note on Friday, March 10th. Finally, Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $18.00. Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) opened at 15.20 on Monday. The stock’s market capitalization is $348.48 million. Oxford Immunotec Global PLC has a 52-week low of $7.73 and a 52-week high of $16.13. The firm has a 50-day moving average of $14.68 and a 200 day moving average of $14.56.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Oxford Immunotec Global PLC had a negative net margin of 30.17% and a negative return on equity of 28.36%. The firm had revenue of $21.51 million during the quarter, compared to analyst estimates of $21.17 million. Equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.09) EPS for the current fiscal year. In related news, VP Elizabeth M. Keiley sold 3,000 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $16.05, for a total transaction of $48,150.00. Following the transaction, the vice president now directly owns 25,429 shares in the company, valued at $408,135.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Wrighton-Smith sold 30,000 shares of the firm’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $15.43, for a total value of $462,900.00. Following the transaction, the chief executive officer now owns 491,668 shares in the company, valued at $7,586,437.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,000 shares of company stock valued at $1,312,860. Company insiders own 7.58% of the company’s stock.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Oxford Immunotec Global PLC had a negative net margin of 30.17% and a negative return on equity of 28.36%. The firm had revenue of $21.51 million during the quarter, compared to analyst estimates of $21.17 million. Equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.09) EPS for the current fiscal year. About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:OXFD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment